MD Learning Channel – Free CME Opportunities

Updates in Cardio-Oncology

CME/CE

0.50

Minutes

42

This presentation explains how cardio-oncologists identify and manage cardiac risks from cancer therapies such as anthracyclines, tyrosine kinase inhibitors, and immune checkpoint inhibitors.

Watch

Close

Updates in Cardio-Oncology

This presentation explains how cardio-oncologists identify and manage cardiac risks from cancer therapies such as anthracyclines, tyrosine kinase inhibitors, and immune checkpoint inhibitors. By stratifying patient risk, adjusting treatment plans, and using targeted medications and monitoring tools, they address numerous complications (heart failure, arrhythmias, and hypertension). Learn from real case studies the complex considerations involved in managing cardiac risk and explore the ongoing follow-up care survivors may need.

Take CME Post-Test

Disclosure Information
Planners:
Ronan O’Beirne, EdD, MBA | Director, UAB Continuing Medical Education
Katelyn Hiden | Physician Marketing Manager, UAB Health System
The planners have no relevant financial relationships with ineligible companies to disclose.

Faculty:
Carrie Lenneman, MSCI, MD | Associate Professor, Cardio-Oncology & Cardiology
Dr. Lenneman has no relevant financial relationships with ineligible companies to disclose. There is no commercial support for this activity.

Accreditation Statement: The University of Alabama School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Alabama School of Medicine designates this online enduring material activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.